Raoul S. Concepcion, MD, FACS

Raoul S. Concepcion, MD, FACS

The Comprehensive Prostate Center

Nashville, TN

Raoul S. Concepcion, MD, FACS, is the current Director of The Comprehensive Prostate Center in Nashville, TN, and also has an appointment as a Clinical Associate Professor of Urology at Vanderbilt University School of Medicine. He served as a resident in General Surgery and Urology at Vanderbilt from 1984 to 1990. Dr. Concepcion’s clinical interests revolve around advanced prostate and bladder cancer management. He is a past president of LUGPA and, along with two other urologists, founded CUSP, a urologic research consortium in the United States. Additionally, he serves as the Chief Urologic Clinical Officer for Integra Connect (West Palm Beach, FL) and is the current editor for Urologists in Cancer Care.

Articles by Raoul S. Concepcion, MD, FACS

The Effect of Local Antibiogram-Based Augmented Antibiotic Prophylaxis on Infection-Related Complications Following Prostate Biopsy

Raoul S. Concepcion, MD, FACS, and E. David Crawford, MD, discuss a recent study Dr. Concepcion was involved with that looked at antibiotic-augmented prophylaxis based on local antibiograms as a method of reducing infections from prostate biopsies. They discuss the design and rationale of the study and methods for administering the prophylaxis, as well as the results, which showed a 53% reduction in infectious complications compared to historical data.

Read More

New Considerations for Oligometastatic Prostate Cancer

Raoul S. Concepcion, MD, FACS, discusses the management of patients with oligometastatic prostate cancer. Currently, there is no standard definition of what defines oligometastatic.  Additionally, questions remain about the handling of the primary tumor in this setting, as well as whether therapy directed at the primary has a long term benefit in overall survival.

Read More

AR-V7 Predicts Response in CRPC

Raoul S. Concepcion, MD, FACS, emphasizes the need for more effective biomarkers when determining adequate treatment for patients with castrate-resistant prostate cancer (CRPC). Concurrently, he compares the findings of studies exploring various options, including the AR-V7 splice variant.

Read More

Join the GRU Community

- Why Join? -